Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet

NCT00954304 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: HM30181AK 1mg
DRUG: HM30181AK 5mg
DRUG: HM30181AK 15mg
DRUG: HM30181AK 60mg
DRUG: Loperamide 2mg

Sponsor

Hanmi Pharmaceutical Company Limited